Revenue + Forward P/E
Bio-Rad Laboratories, Inc. (BIO) quarterly revenue and forward P/EForward P/E: 35.1x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$9.68B
Enterprise value
$9.34B
P/E ratio (TTM)
51.27x
P/S ratio (TTM)
3.27x
P/B ratio
1.23x
EV/Sales
3.61x
EV/EBITDA
19.89x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$2.58B
Gross profit (TTM)
$1.34B
Operating income (TTM)
$270.50M
EBITDA (TTM)
$1.25B
Net income (TTM)
$759.90M
Free cash flow (TTM)
$374.60M
Margins & returns
Gross margin
51.87%
Operating margin
9.25%
Profit margin
6.52%
Return on equity
2.40%
Return on assets
1.72%
Per-share metrics
EPS (TTM)
$6.26
Dividend yield
0.00%
Beta
1.08
Capital structure
Cash & equivalents
$531.80M
Total debt
$1.53B
Net debt
$999.20M
Shares outstanding
26.92M
Financial health
Current ratio
5.62
Debt / equity
0.21
Debt / assets
0.14
Interest coverage
5.52
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $630.37B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $442.95B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $364.62B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.71B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $9.68B | 51.27x | 3.27x | 19.89x | - |